CATX250117P5000
- 2.29
- 0.000.00%
Perspective Therapeutics Newsroom
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
Insider Purchase: CEO of $CATX (CATX) Buys 6,600 Shares
Perspective Therapeutics Downgraded to Neutral From Buy at BofA
Perspective Therapeutics Is Maintained at Outperform by RBC Capital
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6
B of A Securities Downgrades Perspective Therapeutics to Neutral, Lowers Price Target to $6
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16
RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk
Cautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety Concerns
Express News | Perspective Therapeutics Inc : BofA Global Research Cuts to Neutral From Buy; Cuts Price Objective to $6 From $24
Perspective Therapeutics Price Target Cut to $16.00/Share From $22.00 by Oppenheimer
Perspective Therapeutics Is Maintained at Outperform by Oppenheimer
Perspective Therapeutics Analyst Ratings
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16
Truist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)
Perspective Therapeutics Selloff a Buying Opportunity, Says JonesResearch
Cautious Optimism: Justin Walsh's Buy Rating on Perspective Therapeutics Amidst Mixed Trial Results
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Promising Potential in Perspective Therapeutics' VMT-alpha-NET Program Amid Market Hesitations
Perspective Therapeutics Pursuing Dose Escalation Study in Neuroendocrine Tumors